Reference Library
Published Research
Peer-reviewed literature on the compounds in our catalog, linked to PubMed.
For informational reference only. All Dr. Peptide Labs products are sold strictly for laboratory research and identification use — not for human or animal use. The studies below were conducted by independent researchers on the named compounds; they are not studies of our products, and their inclusion makes no claim about product effects. Summaries are descriptive only.
ARA-290 ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice Anesthesiology, 2011
Examined neuropathic pain models in rats and knockout mice.
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study Molecular Medicine, 2012
Randomized double-blind pilot in sarcoidosis small-fiber neuropathy.
ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response Molecular Pain, 2014
Examined spinal microglia response in neuropathic pain models.
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes Molecular Medicine, 2015
Randomized trial measuring metabolic and neuropathic endpoints in type 2 diabetes.
Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke CNS Neuroscience & Therapeutics, 2024
Examined a cerebral ischemia model in mice.
Cagrilintide Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial The Lancet, 2021
Phase 1b trial of cagrilintide co-administered with semaglutide.
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial The Lancet, 2021
Phase 2 dose-finding trial of once-weekly cagrilintide in overweight/obesity.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity The New England Journal of Medicine, 2025
Phase 3 trial of co-administered cagrilintide and semaglutide in overweight/obesity.
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes The New England Journal of Medicine, 2025
Phase 3 trial of the combination in type 2 diabetes.
CJC-1295 Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults The Journal of Clinical Endocrinology and Metabolism, 2006
Measured GH and IGF-I secretion in healthy adults.
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse American Journal of Physiology. Endocrinology and Metabolism, 2006
Examined growth normalization in GHRH knockout mice.
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog The Journal of Clinical Endocrinology and Metabolism, 2006
Examined GH pulsatility during continuous stimulation in humans.
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects Growth Hormone & IGF Research, 2009
Measured serum protein profile changes in adults.
GLP3-RT LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Cell Metabolism, 2022
Reported preclinical characterization and first-in-human single-dose data for the triple receptor agonist.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial The Lancet, 2022
Phase 1b multiple-ascending-dose trial in people with type 2 diabetes.
Thymosin Alpha-1 The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial Journal of Viral Hepatitis, 2005
Randomized clinical trial in chronic hepatitis B.
The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial Critical Care, 2013
Multicenter randomized trial in severe sepsis (ETASS).
Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial Intensive Care Medicine, 2022
Multicentre double-blind randomized trial in acute necrotising pancreatitis.
A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection The Journal of Infectious Diseases, 2023
Pilot trial in hospitalized COVID-19 patients.
The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial BMJ, 2025
Phase 3 randomized placebo-controlled sepsis trial (TESTS).